NetwoRx Bio is developing a system to decode and map the complex communication between immune, tumor, and stroma cells within the tumor microenvironment.Using proprietary computational tools, the company generates the ‘NetwoRx Map Score’ – a patient-specific metric that identifies the most relevant molecular interactions.This score is designed to predict response to immunotherapeutic drugs (ICI), monoclonal antibodies and small molecule immune modulators – unlocking the next generation of immunotherapy.Initial clinical data suggest that NetwoRx Bio Map Scores can predict individual patients' clinical benefit from IO or biological therapy in a cancer agnostic manner.

The company already has highly detailed and comprehensive data for Renal and Bladder cancers, and we are in process of establishing the same for Liver, Lung, Colon, Brain, and Gastric cancers.